The Food and Drug Administration granted Emergent Biosolutions priority review for its over-the-counter Narcan nasal spray. If approved, it would become the first non-prescription version of naloxone to be used to fight the opioid epidemic in the U.S. (Reuters)
Gossamer Bio’s experimental pulmonary arterial hypertension drug reached the main goal in a Phase II trial, but with a smaller effect than expected. The drug, seralutinib, lowered pressure in lung arteries by 14%, but that was not considered clinically meaningful improvement. (STAT News)
Neuralink staff claimed Elon Musk’s demands to rush brain implant trials led to the needless deaths of 1,500 animals. The Department of Agriculture’s Inspector General reportedly opened the probe in recent months at the request of a federal prosecutor. (Fortune)
A large study found myocarditis after receiving a COVID-19 vaccine jab is low among teens and young adults. Most of the cases occurred in male teens and young adults and usually after the second dose of a primary series of either the Pfizer-BioNTech or Moderna vaccine. (NBC News)
A tweet drew attention to a lawsuit accusing CVS of fundraising fraud at checkout and now the healthcare giant has filed a motion to dismiss the suit. Details of the lawsuit, which was filed in May, were shared on social media earlier this week and caused a public outcry. (The Boston Globe)
